Sugi Predict

Sugi Predict / Compounds / SCHEMBL94105

SCHEMBL94105

SCHEMBL94105

C[C@]12CCC(=O)C=C1CC[C@H]1[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12C1CC(=O)C=C2CC[C@@H]3[C@H]([C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)CO)[C@]21C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 10/20 0.63
▸ HSD17B10 Q99714 6/20 0.63
▸ NR3C1 P04150 5/20 0.63
▸ CYP2C19 P33261 5/20 0.63
▸ SERPINA6 P08185 5/20 0.63
▸ PGR P06401 4/20 0.63
▸ CYP3A4 P08684 4/20 0.63
▸ SMN1; SMN2 Q16637 3/20 0.63
▸ NR3C2 P08235 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ SHBG P04278 2/20 0.63
▸ MAPT P10636 1/20 0.63
▸ NFKB1 P19838 1/20 0.63
▸ ALDH1A1 P00352 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ AR P10275 2/20 0.54
▸ ABCB11 O95342 1/20 0.54
▸ TNF P01375 1/20 0.54
▸ IL6 P05231 1/20 0.54
▸ GLUL P15104 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28318620 0.97 HIF1A (0.60) HIF1AHSD17B10NR3C1CYP2C19SERPINA6
SCHEMBL8061818 0.96 HIF1A (0.59) HIF1AHSD17B10NR3C1CYP2C19SERPINA6
SCHEMBL6370137 0.96 HIF1A (0.59) HIF1AHSD17B10NR3C1CYP2C19SERPINA6
Butyric Acid SCHEMBL28142317 0.94 HIF1A (0.57) HIF1AHSD17B10NR3C1CYP2C19SERPINA6
SCHEMBL7766720 0.91 HIF1A (0.55) HIF1AHSD17B10NR3C1CYP2C19SERPINA6
SCHEMBL7973569 0.90 NR3C2 (0.63) HIF1AHSD17B10NR3C1CYP2C19SERPINA6
SCHEMBL24461 0.89 SERPINA6 (0.57) HIF1AHSD17B10NR3C1CYP2C19SERPINA6
SCHEMBL2981243 0.88 HSD17B10 (0.60) HIF1AHSD17B10NR3C1CYP2C19SERPINA6
SCHEMBL2330386 0.87 NR3C1 (0.59) HIF1AHSD17B10NR3C1CYP2C19SERPINA6
SCHEMBL10949810 0.86 NR3C1 (0.54) HIF1AHSD17B10NR3C1CYP2C19SERPINA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109055546-A Predict the method and DNA methylation marker of weightless bone loss cortisol Cortisol Upside Risk 中国航天员科研训练中心 2018-12-21 — — CN claimed
CN-102933218-A Posology and administration of glucocorticoid based compositions DUOCORT PHARMA AB 2013-02-13 — — CN claimed
US-20090264390-A1 Topical Personal Care Compositions And Methods of Use Pure USA, LLC 2009-10-22 — — US claimed
US-20060177471-A1 Topical personal care compositions and methods of use Pure USA, LLC 2006-08-10 — — US claimed
EP-4399208-A1 IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS Rigel Pharmaceuticals, Inc. (US) 2024-07-17 — — EP disclosed
CN-118290357-A Heterocyclic compounds useful in the treatment of disease 艾匹根生物技术有限公司 2024-07-05 — — CN disclosed
CN-118043049-A Sotosib and EGFR antibodies for the treatment of cancers comprising KRAS G12C mutations 安进公司 2024-05-14 — — CN disclosed
CN-117224679-A Application of selective CDK9 regulator in preparation of adrenocortical carcinoma drugs 上海交通大学医学院附属瑞金医院 2023-12-15 — — CN disclosed
CN-117004554-A Culture medium of woody musk gland cells and culture method of woody musk gland cells 北京燕麝生物科技发展有限公司 2023-11-07 — — CN disclosed
WO-2023164122-A2 SYSTEMS, METHOD, AND APPARATUS FOR PROVIDING PERSONALIZED MEDICAL DATA JOHNSON & JOHNSON CONSUMER INC. (US) 2023-08-31 — — WO disclosed
CN-114058592-B Immortalized yak rumen epithelial cell line and construction method thereof 四川农业大学 2023-07-04 — — CN disclosed
WO-2023080753-A1 PHARMACEUTICAL KIT FOR PARENTERAL CO-ADMINISTRATION 주식회사 지투지바이오 2023-05-11 — — WO disclosed
EP-1448231-A1 TOPICAL DELIVERY OF CODRUGS Control Delivery Systems, Inc. (US) 2004-08-25 — — EP disclosed
EP-1365809-A2 METHODS FOR REDUCING CHRONIC STRESS IN MAMMALS Johnson & Johnson Consumer Companies, Inc. (US) 2003-12-03 — — EP disclosed
US-20030118528-A1 Topical delivery of codrugs CONTROL DELIVERY SYSTEMS, INC. 2003-06-26 — — US disclosed
WO-2003043657-A1 TOPICAL DELIVERY OF CODRUGS CONTROL DELIVERY SYSTEMS, INC. (US) 2003-05-30 — — WO disclosed
WO-2002049629-A2 METHODS FOR REDUCING CHRONIC STRESS IN MAMMALS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2002-06-27 — — WO disclosed
US-5296347-A Contacting sample with antibody receptor which binds analyte, linking with bridge receptor, linking with solid phase, detecting analyte CIBA CORNING DIAGNOSTICS CORP. (US) 1994-03-22 — — US disclosed
WO-1993017335-A1 BRIDGE IMMUNOASSAY TRITON DIAGNOSTICS, INC. (US) 1993-09-02 — — WO disclosed
US-4081525-A ELIMINATION OF SERUM PROTEIN INACTIVATION STEP BECKMAN INSTRUMENTS, INC. (US) 1978-03-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030118528-A1 Topical delivery of codrugs DSG1, CCR7, CUTA HIF1A 3782/4885HSD17B10 485/4885NR3C1 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.